We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+9.35%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$846M
AUM Growth
+$95.3M
Cap. Flow
+$37.1M
Cap. Flow %
4.39%
Top 10 Hldgs %
28.99%
Holding
143
New
11
Increased
56
Reduced
23
Closed
11

Top Buys

Rank Stock Value
1
EW icon
Edwards Lifesciences
EW
+$7.11M
2
IART icon
Integra LifeSciences
IART
+$6.94M
3
CI icon
Cigna
CI
+$6.83M
4
ALKS icon
Alkermes
ALKS
+$5.7M
5
IQV icon
IQVIA
IQV
+$5.62M

Top Sells

Rank Stock Value
1
AKRX
Akorn Inc
AKRX
+$11.9M
2
CNC icon
Centene
CNC
+$9.33M
3
INCY icon
Incyte
INCY
+$8.09M
4
LGND icon
Ligand Pharmaceuticals
LGND
+$6.18M
5
ALR
Alere Inc
ALR
+$5.78M

Sector Composition

Rank Sector Weight
1 Healthcare 92.73%
2 Financials 0.93%
3 Industrials 0.27%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SYK icon
26
Stryker
SYK
$123B
$11.7M 1.38%
84,300
-38,270
-31% -$5.25M
IONS icon
27
Ionis Pharmaceuticals
IONS
$8.99B
$11.4M 1.35%
224,562
+19,309
+9% +$899K
ZBH icon
28
Zimmer Biomet
ZBH
$17.6B
$11.3M 1.34%
90,640
– –
ALXN
29
DELISTED
Alexion Pharmaceuticals
ALXN
$11.2M 1.32%
92,000
+21,000
+30% +$2.44M
COR icon
30
Cencora
COR
$59.9B
$10.7M 1.26%
113,058
+10,959
+11% +$976K
EGRX
31
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$10.4M 1.23%
131,990
+64,290
+95% +$5.26M
VTRS icon
32
Viatris
VTRS
$20.1B
$10.2M 1.21%
263,200
+6,000
+2% +$230K
BDX icon
33
Becton Dickinson
BDX
$43.6B
$10.1M 1.2%
53,300
+22,550
+73% +$4.12M
ALNY icon
34
Alnylam Pharmaceuticals
ALNY
$35.7B
$9.97M 1.18%
125,029
-16,871
-12% -$1.08M
TEVA icon
35
Teva Pharmaceuticals
TEVA
$37.3B
$9.48M 1.12%
285,329
-80,843
-22% -$2.5M
WMGI
36
DELISTED
Wright Medical Group Inc
WMGI
$9.24M 1.09%
336,055
+47,392
+16% +$1.34M
SHPG
37
DELISTED
Shire pic
SHPG
$8.91M 1.05%
53,885
-11,815
-18% -$2.06M
VRTX icon
38
Vertex Pharmaceuticals
VRTX
$123B
$8.81M 1.04%
68,400
-7,600
-10% -$915K
IART icon
39
Integra LifeSciences
IART
$1.5B
$8.74M 1.03%
160,350
+145,350
+969% +$6.94M
HRC
40
DELISTED
HILL-ROM HOLDINGS, INC.
HRC
$8.32M 0.98%
104,503
+2,229
+2% +$168K
ABBV icon
41
AbbVie
ABBV
$450B
$8.31M 0.98%
114,574
+11,873
+12% +$798K
MNK
42
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
$8.29M 0.98%
184,945
+2,220
+1% +$97.4K
ALKS icon
43
Alkermes
ALKS
$8.79B
$7.98M 0.94%
137,600
+98,100
+248% +$5.7M
LH icon
44
Labcorp
LH
$23.2B
$7.92M 0.94%
59,795
+44,663
+295% +$5.47M
AET
45
DELISTED
Aetna Inc
AET
$7.87M 0.93%
51,800
+9,200
+22% +$1.3M
LGND icon
46
Ligand Pharmaceuticals
LGND
$6.08B
$7.7M 0.91%
101,630
-88,390
-47% -$6.18M
PRGO icon
47
Perrigo
PRGO
$1.48B
$7.29M 0.86%
96,468
+2,057
+2% +$147K
AGN
48
DELISTED
Allergan plc
AGN
$7.05M 0.83%
29,000
– –
HUM icon
49
Humana
HUM
$48B
$6.38M 0.75%
26,500
+7,500
+39% +$1.7M
THC icon
50
Tenet Healthcare
THC
$16.8B
$6.35M 0.75%
328,506
+2,960
+0.9% +$51.6K
1
2
3 4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q2 2017 Portfolio in Review

As of Q2 2017, Bellevue Group held 143 positions worth $846M, up 13% from $750M the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Bellevue Group deployed $37.1M of net new capital in Q2 2017, opening 11 new positions and adding to 56 existing holdings. Its largest new stake was IQVIA: 66,520 shares worth $5.95M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 92% a quarter earlier, followed by Financials and Industrials.

On the sell side, the largest reduction was Centene, an estimated $9.33M trimmed.

  • Bellevue Group's largest Q2 2017 buy was IQVIA: 66,520 shares worth $5.95M.
  • Bellevue Group added most to Edwards Lifesciences in Q2 2017, an estimated $7.11M increase.
  • Bellevue Group's biggest Q2 2017 reduction was Centene, cutting an estimated $9.33M.
  • Bellevue Group fully exited Akorn Inc in Q2 2017, selling an estimated $11.9M.
  • Bellevue Group's ten largest holdings make up 29% of its $846M portfolio in Q2 2017.
  • Bellevue Group opened 11 new positions and closed 11 in Q2 2017.
  • Bellevue Group's portfolio value rose 13% quarter-over-quarter to $846M.

Based on Bellevue Group's 13F filing for Q2 2017, filed 14 Aug 2017.